Cemiplimab
Based on 1 Customer Validation
Cemiplimab (Anti-Human PD-1) is a high-affinity programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab is commonly used in squamous cell skin cancer research.
For research use only. We do not sell to patients.
- Purity: 99.89%
- CAS No.: 1801342-60-8
- Molecular Weight:143.57 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG4 kappa
Human
PDCD1/PD-1/CD279
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female human PD-1×LAG-3 knockin mice (8-10 weeks) with MC38.Ova cells[2]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection; five injections within 2 weeks
-
Result:Partially inhibited the growth of MC38.Ova tumors and prolonged the survival of mice by administering alone.
Significantly increased the proportion of CD4+ TILs in IFNγ and TNFα by combined immunotherapy with REGN3767.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Immobilized Human PD-1 Protein (ECD, His Tag) can bind Cemiplimab. The EC50 for this effect is 1.73 ng/mL. -
Flow cytometric analysis of 1X106 10 ng/mL PMA and 1 μg/mL Ionomycin co-stimulated Jurkat cells (24h) labeling Cemiplimab (HY-P99203, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1801342-60-8
-
Appearance Liquid
-
Molecular Weight 143.57 kDa
-
Color Colorless to light yellow
-
SMILES
[Cemiplimab]
-
Synonyms
REGN-2810; SAR-439684
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Michael R Migden, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 Jul 26;379(4):341-351. [Content Brief]
[2]. Elena Burova, et al. Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice. Mol Cancer Ther. 2019 Nov;18(11):2051-2062. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)